Key result
Advanced CKM syndrome affects ~13% of US adults, with low kidney disease awareness.
Why the study?
National estimates of cardiovascular-kidney-metabolic stages and condition-specific indicators among US adults were lacking, with limited geographic surveillance data.
Cross-Sectional (n=5,006)
Yes
Answers are grounded in this paper and cite their sources.
Approximately one in eight US adults has advanced CKM syndrome, among whom over 80% with laboratory kidney abnormalities do not report kidney disease and over half with hypertension or diabetes have above-threshold blood pressure or HbA1c, highlighting major national gaps in disease awareness and cardiometabolic risk control.
Objective To describe cardiovascular-kidney-metabolic (CKM) stages and condition-specific indicators among adults in the United States, with exploratory state profiles. Methods: We analyzed 5006 United States adults aged ≥20 years in the National Health and Nutrition Examination Survey, August 2021–August 2023. Survey weights and condition-specific denominators were used. A stage-3 model developed among adults without reported cardiovascular disease was applied to the 2023 Behavioral Risk Factor Surveillance System. Results Advanced CKM (stages 3–4) affected 13.0% (95% confidence interval, 11.6%, 14.4%) of adults. Among advanced-CKM adults with a single-visit kidney abnormality, 80.7% did not report weak or failing kidneys. Within applicable subgroups, 58.7% had blood pressure ≥ 130/80 mm Hg and 56.0% had glycated hemoglobin ≥7%. Concurrent elevation affected 34.1% (95% confidence interval, 24.7%, 44.4%) of the fixed hypertension-plus-diabetes subgroup (91/277). Across 49 jurisdictions, the age-standardized modeled stage-3 contribution ranged from 4.4% to 6.5%; directly reported cardiovascular disease was presented separately. Conclusions National estimates describe frequent condition-specific abnormalities within advanced CKM, while the separate geographic projections provide exploratory surveillance context. Fixed thresholds do not establish individual treatment failure, and state projections require external validation.
No takes yet. Share an insight, caveat, or question.
Zho et al. (2026) conducted a cross-sectional in Cardiovascular-kidney-metabolic (CKM) syndrome (n=5,006). Advanced cardiovascular-kidney-metabolic (CKM) syndrome (stages 3-4) was evaluated on Prevalence of advanced cardiovascular-kidney-metabolic (CKM) syndrome (stages 3-4) (95% CI 11.6-14.4). Advanced CKM syndrome (stages 3-4) affected 13.0% of US adults, with 80.7% of those with kidney abnormalities not reporting weak or failing kidneys.
Synapse has enriched 10 related papers. Consider them for comparative context: